Basilea Pharmaceutica Ltd is auditing clinical data for its broad-spectrum cephalosporin antibiotic, ceftobiprole, with a view to making a future regulatory filing. This follows problems with earlier studies conducted by licensee, Johnson & Johnson. ---Subscribe to MedNous to access this article--- Company News